Compare · PEPG vs TRDA
PEPG vs TRDA
Side-by-side comparison of PepGen Inc. (PEPG) and Entrada Therapeutics Inc. (TRDA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PEPG and TRDA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PEPG is the larger of the two at $370.4M, about 2.0x TRDA ($181.7M).
- Over the past year, PEPG is down 22.8% and TRDA is down 49.3% - PEPG leads by 26.4 points.
- PEPG has been more active in the news (12 items in the past 4 weeks vs 4 for TRDA).
- TRDA has more recent analyst coverage (10 ratings vs 6 for PEPG).
- Company
- PepGen Inc.
- Entrada Therapeutics Inc.
- Price
- -
- -
- Market cap
- $370.4M
- $181.7M
- 1M return
- +44.14%
- +0.11%
- 1Y return
- -22.84%
- -49.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2021
- News (4w)
- 12
- 4
- Recent ratings
- 6
- 10
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Entrada Therapeutics Inc.
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Latest PEPG
- Amendment: SEC Form SCHEDULE 13D/A filed by PepGen Inc.
- Director Ra Capital Management, L.P. bought $43,125,000 worth of shares (8,625,000 units at $5.00) (SEC Form 4)
- PepGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by PepGen Inc.
- PepGen Announces Pricing of $125 Million Public Offering
- SEC Form 424B5 filed by PepGen Inc.
- PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
- PepGen upgraded by BofA Securities with a new price target
- PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form 10-Q filed by PepGen Inc.
Latest TRDA
- Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
- SEC Form 10-Q filed by Entrada Therapeutics Inc.
- Entrada Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Entrada Therapeutics Reports Third Quarter 2026 Financial Results
- Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
- SEC Form 8-K filed by Entrada Therapeutics Inc.
- Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
- Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
- Amendment: SEC Form SCHEDULE 13D/A filed by Entrada Therapeutics Inc.
- Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program